TaiMed Biologics (4147) - Net Assets

Latest as of June 2026: NT$3.68 Billion TWD ≈ $115.83 Million USD

Based on the latest financial reports, TaiMed Biologics (4147) has net assets worth NT$3.68 Billion TWD (≈ $115.83 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$4.50 Billion ≈ $141.81 Million USD) and total liabilities (NT$824.49 Million ≈ $25.98 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 4147 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric	Value
Current Net Assets	NT$3.68 Billion
% of Total Assets	81.68%
Annual Growth Rate	12.36%
5-Year Change	31.15%
10-Year Change	-18.16%
Growth Volatility	62.02

TaiMed Biologics - Net Assets Trend (2009–2025)

This chart illustrates how TaiMed Biologics's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see TaiMed Biologics market cap and net worth.

Annual Net Assets for TaiMed Biologics (2009–2025)

The table below shows the annual net assets of TaiMed Biologics from 2009 to 2025. Also explore 4147 shareholders equity momentum to track the company's year-over-year net asset growth rate.

Year	Net Assets	Change
2025-12-31	NT$3.86 Billion ≈ $121.54 Million	-4.11%
2024-12-31	NT$4.02 Billion ≈ $126.74 Million	+56.77%
2023-12-31	NT$2.57 Billion ≈ $80.85 Million	-5.48%
2022-12-31	NT$2.71 Billion ≈ $85.53 Million	-7.70%
2021-12-31	NT$2.94 Billion ≈ $92.67 Million	-13.89%
2020-12-31	NT$3.42 Billion ≈ $107.62 Million	-4.75%
2019-12-31	NT$3.59 Billion ≈ $112.99 Million	-12.11%
2018-12-31	NT$4.08 Billion ≈ $128.56 Million	-4.93%
2017-12-31	NT$4.29 Billion ≈ $135.23 Million	-8.94%
2016-12-31	NT$4.71 Billion ≈ $148.51 Million	-3.80%
2015-12-31	NT$4.90 Billion ≈ $154.37 Million	+167.70%
2014-12-31	NT$1.83 Billion ≈ $57.67 Million	+178.28%
2013-12-31	NT$657.73 Million ≈ $20.72 Million	+1.94%
2012-12-31	NT$645.21 Million ≈ $20.33 Million	-23.12%
2011-12-31	NT$839.24 Million ≈ $26.44 Million	-19.39%
2010-12-31	NT$1.04 Billion ≈ $32.80 Million	+74.06%
2009-12-31	NT$598.14 Million ≈ $18.84 Million	--

Equity Component Analysis

This analysis shows how different components contribute to TaiMed Biologics's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 130416300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Other Components	NT$5.16 Billion	133.81%
Total Equity	NT$3.86 Billion	100.00%

TaiMed Biologics Competitors by Market Cap

The table below lists competitors of TaiMed Biologics ranked by their market capitalization.

Company	Market Cap
Raydium Semi-Conductor TW:3592	$536.52 Million
Zhejiang Gongdong Medical Technology Co Ltd SHG:605369	$536.57 Million
JinkoSolar Holding Company Limited NYSE:JKS	$536.67 Million
MOIL Limited NSE:MOIL	$536.69 Million
PDS Limited NSE:PDSL	$536.36 Million
Lu Thai Textile Co Ltd SHE:000726	$536.35 Million
Nexpoint Residential Trust Inc NYSE:NXRT	$536.34 Million
Harson Trading China Co Ltd SHG:603958	$536.06 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in TaiMed Biologics's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 4,022,909,000 to 3,857,689,000, a change of -165,220,000 (-4.1%).
Net loss of 167,776,000 reduced equity.
New share issuances of 8,780,000 increased equity.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	NT$-167.78 Million	-4.35%
Share Issuances	NT$8.78 Million	+0.23%
Other Changes	NT$-6.22 Million	-0.16%
Total Change	NT$-	-4.11%

Book Value vs Market Value Analysis

This analysis compares TaiMed Biologics's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 4.45x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has increased from 3.67x to 4.45x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	NT$17.15	NT$62.90	x
2018-12-31	NT$16.23	NT$62.90	x
2019-12-31	NT$14.22	NT$62.90	x
2020-12-31	NT$13.54	NT$62.90	x
2021-12-31	NT$11.66	NT$62.90	x
2022-12-31	NT$10.75	NT$62.90	x
2023-12-31	NT$10.00	NT$62.90	x
2024-12-31	NT$14.73	NT$62.90	x
2025-12-31	NT$14.12	NT$62.90	x

Capital Efficiency Dashboard

This dashboard shows how efficiently TaiMed Biologics utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -4.35%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -27.44%
• Asset Turnover: 0.13x
• Equity Multiplier: 1.25x
Recent ROE (-4.35%) is above the historical average (-9.10%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2015	-9.63%	0.00%	0.00x	1.01x	NT$-961.66 Million
2016	-5.98%	-13581.98%	0.00x	1.02x	NT$-753.34 Million
2017	-12.22%	-6218.04%	0.00x	1.05x	NT$-953.78 Million
2018	-7.88%	-133.47%	0.05x	1.17x	NT$-729.76 Million
2019	-16.13%	-82.14%	0.15x	1.32x	NT$-937.29 Million
2020	-5.37%	-25.37%	0.14x	1.52x	NT$-524.89 Million
2021	-16.01%	-113.91%	0.09x	1.57x	NT$-765.08 Million
2022	-9.92%	-47.83%	0.14x	1.51x	NT$-540.78 Million
2023	-7.59%	-39.61%	0.13x	1.52x	NT$-451.42 Million
2024	-5.02%	-33.08%	0.12x	1.24x	NT$-604.12 Million
2025	-4.35%	-27.44%	0.13x	1.25x	NT$-553.54 Million

Industry Comparison

This section compares TaiMed Biologics's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $1,269,277,700
Average return on equity (ROE) among peers: 3.23%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
TaiMed Biologics (4147)	NT$3.68 Billion	-9.63%	0.22x	$536.45 Million
Apex Biotechnology Corp (1733)	$1.65 Billion	5.76%	0.61x	$94.94 Million
Sinphar Pharmaceutical Co Ltd (1734)	$2.16 Billion	5.13%	0.72x	$196.55 Million
Panion & BF Biotech Inc (1760)	$324.61 Million	1.57%	1.69x	$144.79 Million
Chunghwa Chemical Synthesis & Biotech Co Ltd (1762)	$1.82 Billion	4.71%	0.89x	$82.64 Million
SYN-Tech Chem & Pharm Co Ltd (1777)	$2.56 Billion	15.36%	0.11x	$104.38 Million
Level Biotechnology (3118)	$529.43 Million	10.96%	0.46x	$32.36 Million
GenMont Biotech Inc (3164)	$861.62 Million	3.30%	0.66x	$42.95 Million
Medigen Biotechnology (3176)	$807.90 Million	0.00%	0.08x	$167.66 Million
Sagittarius Life Science (3205)	$531.71 Million	-16.25%	0.27x	$100.02 Million
Genovate Biotechnology Co Ltd (4130)	$1.45 Billion	1.77%	0.10x	$115.03 Million

About TaiMed Biologics

TWO:4147 Taiwan Biotechnology

Market Cap

$536.45 Million

NT$17.03 Billion TWD

Market Cap Rank

#11998 Global

#436 in Taiwan

Share Price

NT$62.90

Change (1 day)

+0.64%

52-Week Range

NT$47.10 - NT$77.40

All Time High

NT$341.00